We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · August 01, 2021

Pharmacokinetic–Pharmacodynamic Vedolizumab Model Targets Endoscopic Remission in CD

Inflammatory Bowel Diseases


Additional Info

Disclosure statements are available on the authors' profiles:

Inflammatory Bowel Diseases
Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
Inflamm. Bowel Dis. 2021 Jun 17;[EPub Ahead of Print], J Hanzel, E Dreesen, S Vermeire, M Löwenberg, F Hoentjen, P Bossuyt, E Clasquin, FJ Baert, GR D'Haens, R Mathôt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading